31.01.2024 18:28 | MOS, DEST, AAU | EARNINGS AND TRADING: STV raises holding in Two Cities Television | Alliance |
31.01.2024 07:00 | DEST | Clinical development update | RNS |
22.01.2024 07:00 | DEST | Appointment of Nominated Adviser and Sole Broker | RNS |
04.01.2024 14:07 | DEST | Destiny Pharma seeks to capitalise on XF-73 market potential in 2024 | Alliance |
04.01.2024 07:00 | DEST | Year End Business Update | RNS |
20.10.2023 07:00 | DEST | Grant of Share Options | RNS |
19.10.2023 07:00 | DEST | Director/PDMR Shareholding | RNS |
17.10.2023 11:15 | DEST | Destiny Pharma celebrates study findings on "potent" flagship drug | Alliance |
17.10.2023 10:18 | ABDX, DEST, INX | AIM WINNERS & LOSERS: Destiny Pharma posts "landmark" XF-73 data | Alliance |
17.10.2023 07:01 | DEST | XF Pipeline Update Meeting | RNS |
17.10.2023 07:00 | DEST | Publication of new microbiological data for XF-73 | RNS |
10.10.2023 07:00 | DEST | Director/PDMR Shareholding | RNS |
04.10.2023 12:34 | DEST | Director/PDMR Shareholding | RNS |
27.09.2023 07:00 | DEST | Notice of XF Pipeline Update Meeting | RNS |
20.09.2023 14:27 | DPA, ENET, DEST | TRADING UPDATES: Dianomi swings to loss; Epwin revenue up | Alliance |
20.09.2023 07:00 | DEST | Interim Results | RNS |
13.09.2023 15:48 | W7L, SUPR, PYX | UK earnings, trading statements calendar - next 7 days | Alliance |
23.08.2023 07:00 | DEST | Notice of Interim Results | RNS |
31.07.2023 17:31 | IIP, DUKE, MXC | TRADING UPDATES: MGC Pharmaceuticals granted psilocybin import permit | Alliance |
31.07.2023 12:01 | DEST | Publication of new data for XF-73 | RNS |
25.07.2023 14:27 | DEST | IN BRIEF: Destiny Pharma says former Chair Nigel Rudd return to role | Alliance |
25.07.2023 07:00 | DEST | Appointment of new Chairman | RNS |
19.07.2023 13:16 | DEST | IN BRIEF: Destiny Pharma appoints Chris Tovey as CEO; Chair resigns | Alliance |
19.07.2023 12:55 | DEST | Board changes including appointment of new CEO | RNS |
07.07.2023 07:00 | DEST | Exercise of Options and Total Voting Rights | RNS |
06.07.2023 12:49 | DEST | IN BRIEF: Destiny Pharma confirms phase 3 development for lead asset | Alliance |
06.07.2023 07:00 | DEST | Positive findings from recent SAB meeting | Reach |
29.06.2023 18:55 | RNEW, JSE, FARN | TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend | Alliance |
29.06.2023 07:00 | DEST | Business Update | RNS |
26.05.2023 15:27 | DEST | Director/PDMR Shareholding | RNS |
26.05.2023 10:51 | KOO, DEST, POLX | Polarean shares down despite narrowed annual loss and optimism | Alliance |
26.05.2023 07:00 | DEST | Director Dealing | RNS |
25.05.2023 12:23 | DEST | Result of Annual General Meeting | RNS |
25.05.2023 10:42 | GSK, DEST | IN BRIEF: Destiny Pharma picks interim CEO as Clark makes quick exit | Alliance |
25.05.2023 07:00 | DEST | Dr Debra Barker Appointed Interim CEO | RNS |
18.05.2023 15:03 | ZIN, VANQ, TBCG | UK shareholder meetings calendar - next 7 days | Alliance |
12.05.2023 12:24 | DEST | Grant of Share Options | RNS |
02.05.2023 19:22 | PHE, DNE, MACF | TRADING UPDATES: Macfarlane buys A&G Holdings for GBP3.6 million | Alliance |
02.05.2023 07:00 | DEST | Positive results from SPOR-COV® research | RNS |
26.04.2023 16:10 | DEST | Posting of Annual Report and Notice of AGM | RNS |
26.04.2023 10:05 | DEST | Exercise of Options and Total Voting Rights | RNS |
13.04.2023 13:59 | DEST | IN BRIEF: Destiny Pharma annual loss widens as expenses grow | Alliance |
13.04.2023 07:00 | DEST | Audited results for year ended 31 December 2022 | RNS |
06.04.2023 15:42 | XPP, TSCO, PZC | UK earnings, trading statements calendar - next 7 days | Alliance |
04.04.2023 07:00 | DEST | Landmark data published on NTCD-M3 | RNS |
03.04.2023 07:00 | DEST | Notice of Results and Investor Presentation | RNS |
24.03.2023 07:00 | DEST | Landmark XF-73 Phase 2 data published in journal | RNS |
16.03.2023 15:29 | DEST | Result of General Meeting and Total Voting Rights | RNS |
16.03.2023 06:54 | DEST | IN BRIEF: Destiny Pharma raises GBP7.3 million total in equity raise | Alliance |
15.03.2023 16:02 | DEST | Result of Open Offer | RNS |
06.03.2023 10:50 | DEST | Exercise of Options and Total Voting Rights | RNS |
06.03.2023 10:31 | DEST | Holding(s) in Company | RNS |
28.02.2023 15:55 | DEST | Posting of Circular and Notice of General Meeting | RNS |
27.02.2023 16:30 | DEST | Director/PDMR Shareholding | RNS |
24.02.2023 14:28 | DEST | Destiny shares fall on fundraise discount despite USD570 million deal | Alliance |
24.02.2023 13:32 | DEST | Issue of Equity | RNS |
24.02.2023 13:32 | DEST | Agreement with Sebela Pharmaceutical for NTCD-M3 | RNS |
24.02.2023 11:00 | DEST | Price Monitoring Extension | RNS |
31.01.2023 11:00 | DEST | Price Monitoring Extension | RNS |
26.01.2023 10:10 | DEST | Exercise of Options and Total Voting Rights | RNS |
25.01.2023 20:03 | PRD, CRCL, PAY | TRADING UPDATES: Appreciate gets court date; Corcel completes sale | Alliance |
25.01.2023 07:00 | DEST | US Center for Disease Control review paper | Reach |
22.12.2022 11:25 | DEST | Destiny Pharma on track for commercial agreement for NTCD-M3 drug | Alliance |
22.12.2022 09:05 | DEST | Second Price Monitoring Extn | RNS |
22.12.2022 09:00 | DEST | Price Monitoring Extension | RNS |
22.12.2022 07:00 | DEST | Year End Trading Update | RNS |
07.12.2022 17:35 | DEST | Destiny Pharma eyes potential billion dollar returns from Nasal asset | Alliance |
07.12.2022 07:00 | DEST | FDA/CDC highlight need for infection preventions | Reach |
07.12.2022 07:00 | DEST | XF-73 Nasal final Phase 3 development plans | RNS |
02.12.2022 14:48 | DEST | Director Disclosure | RNS |
23.11.2022 07:00 | DEST | Appointment of Corporate Broker | RNS |
21.11.2022 14:19 | DEST | EQS-News: Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections | EQS |
18.11.2022 13:16 | DEST | Director Shareholding Amendment | RNS |
15.11.2022 16:16 | DEST | Destiny Pharma starts new drug study for its skin infection treatment | Alliance |
15.11.2022 07:00 | DEST | XF-73 advances to clinically enabling safety study | RNS |